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ABSTRACT
Objective: To assess long-term, cause-specific mortality rates and rate ratios of the patients alive at
1 year after subarachnoid hemorrhage (SAH).
Methods: The population-based, prospective, cohort study with a nested case-control design con-
sisted of 64,349 persons (aged 25–74 years at enrollment) who participated in the National FINRISK
Study between 1972 and 2007. Four hundred thirty-seven SAH cases, 233 one-year SAH survivors,
and their matched intrinsic controls were identified and followed up until the end of 2009 through the
nationwide Finnish Causes of Death Register. All-cause mortality rates and rate ratios of the 1-year
SAH survivors and controls were the main outcome measures.
Results: Eighty-eight (37.8%) of 233 one-year SAH survivors died during the total follow-up time of
2,487person-years (median8.6 years, range0.1–35.8 years). The1-year SAHsurvivors had a hazard
ratio of 1.96 (95% confidence interval 1.57–2.47) for death compared with the matched general
population with 10 controls for each SAH survivor. One-year SAH survivors had up to 31 additional
deaths per 1,000 person-years comparedwith controls with minimal cerebrovascular risk factors. The
higher long-term risk of death amongSAH survivorswas attributed solely to cerebrovascular diseases,
andmost importantmodifiable risk factors for deathwere smoking, high systolic blood pressure ($159
mm Hg), and high cholesterol levels ($7.07 mmol/L).
Conclusion: One-year SAH survivors have excess mortality, which is attributed to an exceptional risk
of deadly cerebrovascular events. Aggressive post-SAH cerebrovascular risk factor intervention strat-
egies are highly warranted. Neurology 2013;80:481–486
GLOSSARY
BP 5 blood pressure; CI 5 confidence interval; HR 5 hazard ratio; ICD 5 International Classification of Diseases; SAH 5
subarachnoid hemorrhage; SMR 5 standardized mortality ratio.
Published data on long-term mortality of survivors of subarachnoid hemorrhage (SAH) are scarce
and limited. Studies, which have been conducted mainly in the computed tomography angiography
era,1–6 suggest that SAH survivors have increased long-term mortality rates compared with a general
population.1,3,4,6 Not only those with the permanent neurologic sequelae of SAH but also survivors
who recover to an independent state from the event seem to have excess long-term mortality.1,5,6
Given that the etiology of SAH is mainly environmental,7 it is understandable that long-term
mortality of SAH survivors exceeds that of the general population. This holds true especially if
post-SAH interventions to minimize exposure to modifiable risk factors are not implemented.
However, implementation of secondary prevention measures is impossible if the conditions and
diseases causing excess mortality are unknown.
Systemic cardiovascular diseases and cancers are common causes of death not only among SAH
survivors1–6 but also among the general population in high-income countries.8,9 In this study, we extracted
1-year SAH survivors and controls from the same large and well-characterized population-based cohort.
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Using intrinsic and detailed controls enabled esti-
mations of the effect of risk factors on long-term
mortality for the first time. Also for the first time,
we analyzed cause-specific, long-term mortality of
1-year SAH survivors.
METHODS The FINRISK cohort. The data were drawn from
the National FINRISK Study database.10 The FINRISK surveys were
initiated in 1972 in selected regions in Finland, and since then the
surveys have been conducted every 5 years. The FINRISK participants
filled in a health-related baseline questionnaire and attended a clinical
examination, which was conducted by research nurses at enrollment.
Using the eighth, ninth, and tenth revisions of the International
Classification of Diseases (ICD), incident cases of SAH were identified
from the National Hospital Discharge Register and from the Causes of
Death Register. The ICD revision used was changed in Finland from
the eighth (ICD-8) to the ninth (ICD-9) in the beginning of 1987,
and from the ICD-9 to the tenth (ICD-10) in the beginning of 1996.
Data were retrieved on all persons listed with a diagnosis of subarach-
noid hemorrhage (ICD-8 and ICD-9 code 430) or nontraumatic sub-
arachnoid hemorrhage (ICD-10 code I60), and identified cases were
linked to the baseline data using unique personal identification num-
bers assigned to all Finnish residents. TheNational Institute for Health
andWelfare administers the Hospital Discharge Register, and all inpa-
tient stays are recorded from all hospitals in Finland. The Causes of
Death Register is administered by the Statistics Finland, where a spe-
cialist physician (forensic medicine) and a nosologist check the consis-
tency of the underlying cause of death and correct the diagnosis if
necessary. According to a Finnish law, a forensic autopsy has to be
done for all people with sudden and unexpected death to confirm
diagnosis. The cause of death of 1-year SAH survivors and all controls
(see below) was divided into 7 categories: 1) cardiovascular, 2) cere-
brovascular, 3) cancer, 4) trauma, 5) psychiatric, 6) infection, and 7)
other. The validity of the register-based diagnosis of SAH that was used
has been verified previously, and the agreement rate and sensitivity for
the recorded SAH diagnoses are 89% to 92%.11,12 The agreement rate
of SAH in the Finnish Causes of Death Register is 95%.12,13
The day of diagnosis was defined as the day of hospitalization for
SAH. Participants were followed from the onset of SAH (defined as
first hospitalization for SAH), whereas censoring occurred at the time
of death or emigration (data from the Finnish Population Register),
or at the end of the follow-up period in December 2009. Follow-
up for all controls started at the same day as the initiation of
follow-up of the matched cases. None of the controls had a history
of SAH. Completeness of follow-up is 100% for deaths and hospital-
izations in Finland. Only 0.4% of the FINRISK study subjects were
lost to follow-up because of emigration.14
The FINRISK cohort consisted of 64,349 Finnish residents, of
which 33,235 (51.7%) were women. Mean age at enrollment was
45.1 years (612 years, range 25–74 years) with no difference by sex
or future case status. Of the 437 identified SAH cases in the FINRISK
cohort, 79 (18.1%) died outside hospitals or at emergency rooms. Of
the remaining 358 hospitalized patients, 95 (26.5%) died during the
first 30 days and an additional 20 (5.6%) during the first year after
hospitalization.
Standard protocol approvals, registrations, and patient
consents. The approval for the FINRISK surveys has been applied
each time from relevant ethics committees. Informed consent (verbal
from 1977 to 1992 and written since 1997) was received from all
participants.
One-year SAH survivors and controls extracted from the
FINRISK cohort. A nested case-control approach was used to
assess differences in the rate and cause of long-term mortality among
study groups. An intrinsic general population group for 1-year SAH
survivors was constructed by selecting 10 controls for each SAH case,
and these controls and cases were matched for enrollment year. Each
control had to be alive and without a prior SAH at the time of SAH
of the case. One-year SAH survivors and the enrollment year–
matched general population group did not differ by sex, age, or region
of residence.
Of the 437 SAH cases, there were 243 (55.6%) one-year SAH
survivors. For the 243 one-year SAH survivors, control selection
using individual matching was contingent on each case characteristic.
Ten 1-year SAH survivors were selected as controls (random selection
from the pool of controls based on eligibility criteria and matching
criteria) because they were healthy at the time of selection (when a
matched case presented) but later had an SAH. Thus, these 10 par-
ticipants (cannot be both a case and a control) were excluded from the
final analyses, which therefore included 233 one-year SAH survivors
(mean age 44.2 years at enrollment). Of these 233 one-year SAH sur-
vivors, 131 (56.2%) were women.
The general population control group included 2,330 partici-
pants (mean age 43.6 years at enrollment), of which 1,256
(53.9%) were women. The general population group was further
divided into 3 subgroups on the basis of our previous study15: 1)
multiple risk factor subgroup, which included only participants
who were current smokers with systolic blood pressure
(BP) $159 mm Hg (highest fifth when using the cutoff points
of quintiles) and had cholesterol levels $5.59 mmol/L (3rd to 5th
fifths when using the cutoff points of quintiles) at enrollment;
2) minimal risk factor subgroup, including only participants who
were never smokers, had systolic BP ,135 mm Hg (1st to 2nd
fifths when using the cutoff points of quintiles), and had cholesterol
levels ,5.59 mmol/L at enrollment; and 3) Gaussian subgroup
“without extremes” (people with multiple and minimal risk factors
excluded), representing people who were not included in the mul-
tiple and minimal risk factor subgroups. The same grouping criteria
were also used to divide the 1-year SAH survivors into the 3 dif-
ferent risk factor subgroups.
The multiple risk factor subgroup, minimal risk factor subgroup,
and Gaussian population subgroup, which were extracted from the
general population controls, included 77, 198, and 2,055 partici-
pants, respectively. Because all controls were selected on the basis
of eligibility criteria and matching criteria at the time of diagnosis
(i.e., when a matched SAH case was diagnosed), a number of
matched controls withdrew (follow-up data ,1 year) before the
actual follow-up started for 1-year SAH survivors. Therefore, for all
subsequent analyses, the multiple risk factor subgroup, minimal risk
factor subgroup, and Gaussian population subgroup included 68,
184, and 1,897 participants, respectively.
Mortality estimates and statistical analyses. The estimation of
hazard ratios (HRs) with 95% confidence intervals (CIs) for death
was calculated using the Cox proportional hazards regression model
with a generalization of the Breslow estimator. A mortality rate ratio
was calculated as a follow-up, time-dependent (person-years) compar-
ison of the number of the observed deaths among 1-year SAH survi-
vors with the number of observed deaths among the matched and
adjusted controls. Mortality rates per 1,000 person-years were calcu-
lated for the study controls. The number of excess deaths per 1,000
person-years was calculated for the 1-year SAH survivors. Cumulative
survival of the controls was depicted using Kaplan-Meier curves, and
differences between the curves were tested for significance by the
log-rank test. Statistical significance was defined as p , 0.05. All
adjustments and statistical analyses were performed using the survival
analysis procedures in the Stata statistical software (version 11.2; Stata
Corp, College Station, TX).
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RESULTS Recorded deaths and follow-up times. Among
the 233 1-year SAH survivors, 88 (37.8%) deaths were
recorded during the follow-up time (time at risk of
death) (table). Of the general population controls of
2,330 participants, there were 506 (21.7%) deaths
(table). The multiple risk factor subgroup, minimal risk
factor subgroup, andGaussian population subgroup had
36 (52.9%), 9 (4.9%), and 461 (24.3%) deaths during
the follow-up times, respectively (table).
HRs for death. In comparison with the matched general
population control group, 1-year SAH survivors had an
HR of 1.96 (95%CI, 1.57–2.47) for death. Comparing
with the Gaussian population subgroup, the multiple
risk factor subgroup, minimal risk factor subgroup, and
1-year SAH survivors had HRs of 2.30 (95% CI, 1.64–
3.23), 0.25 (95% CI, 0.13–0.47), and 1.94 (95% CI,
1.54–2.43) for death (table).
After adding age (continuous), sex (dichotomous),
smoking (divided into never smokers, quit .6 months
ago, quit ,6 months ago, occasional smokers, and cur-
rent smokers), systolic BP values (divided into fifths),
hypertension diagnosis (dichotomous), and total choles-
terol levels (divided into fifths) as covariates for death
into Cox proportional hazards regression analyses, 1-year
SAH survivors had an HR of 1.76 (95%CI, 1.38–2.23)
for death in comparison with the matched general pop-
ulation group. Age (HR 1.09 [95%CI, 1.38–2.23]), the
highest fifth ($159 mm Hg) of systolic BP (HR 1.48
[95% CI, 1.04–2.11]), current smoking (HR 1.88
[95% CI, 1.50–2.34]), and the highest fifth ($7.07
mmol/L) of cholesterol levels (HR 1.57 [95% CI,
1.06–2.34]) were significant risk factors for death among
the whole study population in this multivariate analysis.
Male gender seems to confer a decreased risk for death
1 year after SAH (HR of 0.64 [95% CI, 0.52–0.79]).
Mortality rates and rate ratios. Mortality rates for the mul-
tiple risk factor subgroup, minimal risk factor subgroup,
Gaussian population subgroup, and 1-year SAH survi-
vors are depicted in the table. For 1-year SAH survivors,
the mortality rate ratios were 7.75 (95% CI, 3.90–
17.51), 0.82 (95% CI, 0.55–1.24), and 1.84 (95%
CI, 1.45–2.32) in comparison with the minimal risk
factor, multiple risk factor, and Gaussian population
subgroup, respectively. Survival rates of 1-year SAH sur-
vivors and control subgroups are depicted in a Kaplan-
Meier survival curve (figure 1A).
The effects of risk factors on long-term survival of 1-
year SAH survivors were estimated using a Kaplan-Meier
survival analysis in which 1-year SAH survivors were
divided into 3 subgroups: the multiple risk factor SAH
subgroup, minimal risk factor SAH subgroup, andGaus-
sian population SAH subgroup. Results suggested that
1-year SAH survivors who were current smokers, had
a high systolic BP ($159 mm Hg), and total serum
Table Characteristics of 1-year survivors of SAH and adjusted subgroups
1-year SAH
survivors
Gaussian population
subgroupa
Minimal RF
subgroup
Multiple RF
subgroup
No. of persons 233 1,897 184 68
Females, n (%) 131 (56.2) 1,013 (50.1) 147 (79.9) 11 (16.2)
Deaths, n (%) 88 (36.2) 461 (24.3) 9 (4.9) 36 (52.9)
Age,b y
Mean 57.5 57.7 51.6 58.1
Median 58.4 59.0 51.9 57.4
Follow-up time, y
Total 2,487 24,031 1,972 830
Median (range) 8.6 (0.1–35.8) 11.4 (0–38.8) 8.4 (0–36.1) 10.5 (0.2–29.9)
Current smokers, n (%) 98 (42.0) 502 (26.4) 0 (0.0) 68 (100.0)
Systolic BP ‡159 mm Hg, n (%) 55 (23.6) 352 (18.6) 0 (0.0) 68 (100.0)
Cholesterol ‡5.59 mmol/L, n (%) 171 (73.4) 1,449 (76.4) 0 (0.0) 68 (100.0)
HR for death (95% CI) 1.94 (1.54–2.43) 1 0.25 (0.13–0.47) 2.30 (1.64–3.23)
Mortality rate per 1,000 person-years
(95% CI)
35.4 (28.7–43.6) 19.2 (17.5–21.0) 4.6 (2.4–8.8) 43.4 (31.3–60.2)
Excess deaths per 1,000 person-
yearsc
16 0 NA 24
Abbreviations: BP 5 blood pressure; CI 5 confidence interval; HR 5 hazard ratio; NA 5 not applicable; RF 5 risk factors;
SAH 5 subarachnoid hemorrhage.
aGaussian population subgroup represents the matched general population (see the Methods section).
bMean and median age for each group was calculated using the age of the patient at diagnosis.
c The difference between observed deaths in the adjusted subgroups compared with the Gaussian population subgroup.
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cholesterol levels of$5.59 mmol/L at enrollment had a
much higher risk of death than 1-year SAH survivors
with less risk factors (figure 1B). However, because
of a limited number of the 1-year SAH survivors
with minimal or multiple risk factors, the data are insuf-
ficient to conduct statistically reliable estimates of HRs
for death in these SAH subgroups.
Causes of death. Compared with the matched general
population group, excess deaths of 1-year SAH survivors
were attributed solely to cerebrovascular diseases (figure
2). In the matched general population, cerebrovascular
diseases accounted for only 7.7% of all deaths, whereas
this number was 28.4% for 1-year SAH survivors (figure
2). Ischemic cerebrovascular diseases or their sequelae
accounted for 5.5% and 11.4%, intracerebral hemor-
rhages accounted for 1.4% and 3.4%, SAHs accounted
for 0.2% and 4.5%, and sequelae of SAH accounted for
0% and 6.8% of all deaths in the matched general pop-
ulation and 1-year SAH survivors, respectively.
DISCUSSION The approximately 2 times higher long-
term risk of death among 1-year SAH survivors is attrib-
uted to cerebrovascular diseases, such as brain infarcts
and intracerebral hemorrhages. Changes over time in
the risk of death of 1-year SAH survivors are not notice-
able, suggesting that the higher risk of death cannot be
attributed only to SAH-related health effects in the early
years after SAH, even though sequelae of SAH
accounted for 6.8% of all deaths among 1-year SAH
survivors. After adjustment for multiple cerebrovascular
risk factors, the risk of death among 1-year SAH survi-
vors decreases but still exceeds that of the general popu-
lation. Age, high systolic BP, current smoking, and high
cholesterol levels were significant risk factors for death
among the whole study population. The cutoff values
used for cholesterol levels and high systolic BP were
defined on the basis of previous results,15 and do not
follow any clinical practice guidelines. The risk of death
did not differ significantly between 1-year SAH survi-
vors and the population with multiple risk factors. This
is probably attributable to the fact that 1-year SAH
survivors do not all have multiple risk factors, like the
multiple risk factor controls. In any case, it seems evi-
dent that cerebrovascular risk factor profiles have great
impact on long-term life expectancy in SAH survivors
and people in general, and that the variation in the risk
factor profiles between study groups can explain the vast
difference in mortality estimates. Overall, 1-year SAH
survivors experienced up to 16 and 31 additional deaths
per 1,000 person-years compared with thematched gen-
eral population and population with minimal cerebro-
vascular risk factors, respectively. Those 1-year SAH
survivors who have high systolic BP and high cholesterol
levels, and who are already smokers before an SAH
event, are at greatest risk of post-SAH death. Bearing
in mind the extreme variation in the risk of death, not
only primary but also secondary prevention strategies
addressing smoking, hypertension, and high cholesterol
are warranted.
Previous studies have used varying methods and cri-
teria in studying and reporting long-term mortality rates
of SAH survivors. The largest study to date recently
reported 12% excess mortality of 1-year SAH survivors
at 15 years after SAH.6 Another recent study based on
the International Subarachnoid Aneurysm Trial cohort
observed that the standardized mortality ratio (SMR) of
1-year SAH survivors was 1.57 times that of the general
population.4 A Dutch study published in 2009 con-
cluded that the SMR of all SAH survivors (discharged
alive) was 1.7 times that of the general population.3 A
decade-old Finnish study reported that the SMR of
1-year SAH survivors with good recovery was 2 times
that of the general population.1 Inconsistency in, for
Figure 1 Kaplan-Meier survival analysis
A Kaplan-Meier survival analysis in which the general population controls (A) and 1-year sub-
arachnoid hemorrhage (SAH) survivors (B) are divided into subgroups on the basis of risk
factors: minimal risk factor subgroup (A1), Gaussian control population (A2), 1-year SAH sur-
vivors (A3), multiple risk factor subgroup (A4), 1-year SAH survivors withminimal risk factors
(B1), Gaussian 1-year SAH survivors (B2), 1-year SAH survivors with multiple risk factors
(B3). A1 and B1 5 never smokers with systolic blood pressure (BP) ,135 mm Hg and cho-
lesterol levels ,5.59 mmol/L. A4 and B3 5 smokers with systolic BP $159 mm Hg or cho-
lesterol levels $5.59 mmol/L.
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example, survival statistics, follow-up times, and patient
selection criteria limits conclusive interpretations, but
also the previous results give a reasonable impression that
SAH survivors, despite the neurologic outcome, have
approximately 2 times higher long-term mortality com-
pared with the general population. Causes of reported
excess mortality among SAH survivors were unclear until
this study. Contrary to the current and previous results,
one study suggests that 3 years after SAH, survivors have
a survival rate similar to that of the general population.5
Because SAH is a cerebrovascular disease withmodifiable
risk factors, the contrary results are confusing. The vary-
ing interpretations5 may be attributable to the statistical
methods used and the study population selected. In gen-
eral, adopting cancer survival statistics (with extrinsic
control populations) to cerebrovascular diseases should
be implemented cautiously.
Compared with the previous long-term SAH sur-
vival studies,1–6 the current study has some strengths.
First, the current study had the possibility of matching
and adjusting controls to a variety of covariates assessed
before an SAH event. Our results suggest that differ-
ences in the prevalence of cerebrovascular risk factors in
age- and sex-adjusted study controls can confound mor-
tality estimates. Differences in risk factors of study con-
trols may cause comparisons of mortality rates, for
example, between SAH cohorts treated with microsur-
gery (clipping) or endovascular coiling4 difficult to inter-
pret correctly if matching or adjusting to covariates
cannot be done. Second, the current study was based
on a large, prospective, population-based study, the
FINRISK, whereas most of the previous cohorts were
gathered from 1 or 2 hospitals. The large-scale, popula-
tion-based recording of deaths in the current study may
thus further strengthen the provision of unbiased and
reliable risk estimates of late mortality among SAH sur-
vivors. Third, instead of using a register-based extrinsic
general population as a comparison group, all controls
were intrinsic and extracted from the same main cohort,
the FINRISK. The main drawback in using an extrinsic
general population as a comparison group is that it is
usually less exposed to disease risk factors, all of which
are not always known. Possible drawbacks of the current
study include the fact that register-based data may have
inaccuracies. However, mortality studies in general rely
on population-based cause-of-death registries. Further-
more, the registries used have been utilized for more
than 1,000 scientific publications during the last decades
and their validity has been tested in a number of occa-
sions. A further limitation of the study is that all SAH
patients, not only surgically or endovascularly treated
ones, were included in the study. Thus, the few recur-
rent SAH events among 1-year SAH survivors could
have been caused by aneurysms that were left untreated
in the primary occasion. However, these few SAH
events occurred years after the primary event and the
limited number of them does not skew the results or
interpretations.
Not only high-quality primary treatment of SAH but
also effective secondary prevention of post-SAH cerebro-
vascular events would likely prevent a considerable num-
ber of early deaths. This is especially true for relatively
young SAH survivors. A history of smoking, high systolic
BP, and high cholesterol levels dramatically shortens the
life expectancy of SAH survivors. Long-term SAH mor-
tality studies seem to give a higher estimation of mortal-
ity ratios when SAH survivors are compared with the
general population instead of risk factor–adjusted control
populations. Finding ways to efficiently reduce poten-
tially preventable early deaths of SAH survivors as well as
people with SAH risk factors will be a future challenge.
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Figure 2 Causes of death in 1-year survivors of subarachnoid hemorrhage
(SAH) and matched general population controls
Number of deaths in each category is reported on the top of bars.
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